These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 25974999)

  • 1. Soluble receptor of advanced glycation end-products in patients with acute myocardial infarction treated with remote ischaemic conditioning.
    Jensen LJ; Munk K; Flyvbjerg A; Bøtker HE; Bjerre M
    Clin Lab; 2015; 61(3-4):323-8. PubMed ID: 25974999
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dynamic changes in sRAGE levels and relationship with cardiac function in STEMI patients.
    Jensen LJ; Lindberg S; Hoffmann S; Iversen AZ; Pedersen SH; Møgelvang R; Galatius S; Flyvbjerg A; Jensen JS; Bjerre M
    Clin Biochem; 2015 Mar; 48(4-5):297-301. PubMed ID: 25562186
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of remote ischaemic conditioning on clinical outcomes in patients with acute myocardial infarction (CONDI-2/ERIC-PPCI): a single-blind randomised controlled trial.
    Hausenloy DJ; Kharbanda RK; Møller UK; Ramlall M; Aarøe J; Butler R; Bulluck H; Clayton T; Dana A; Dodd M; Engstrom T; Evans R; Lassen JF; Christensen EF; Garcia-Ruiz JM; Gorog DA; Hjort J; Houghton RF; Ibanez B; Knight R; Lippert FK; Lønborg JT; Maeng M; Milasinovic D; More R; Nicholas JM; Jensen LO; Perkins A; Radovanovic N; Rakhit RD; Ravkilde J; Ryding AD; Schmidt MR; Riddervold IS; Sørensen HT; Stankovic G; Varma M; Webb I; Terkelsen CJ; Greenwood JP; Yellon DM; Bøtker HE;
    Lancet; 2019 Oct; 394(10207):1415-1424. PubMed ID: 31500849
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Soluble receptor of advanced glycated endproducts is associated with plaque vulnerability in patients with acute myocardial infarction.
    Park HJ; Baek JY; Shin WS; Kim DB; Jang SW; Shin DI; Koh YS; Seo SM; Uhm JS; Kim TH; Kim CJ; Kim PJ; Chang K; Chung WS; Seung KB; Lee JM
    Circ J; 2011; 75(7):1685-90. PubMed ID: 21576827
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Soluble form of receptor for advanced glycation end products and incidence of new cardiovascular events among patients with cardiovascular disease.
    Reichert S; Triebert U; Santos AN; Hofmann B; Schaller HG; Schlitt A; Schulz S
    Atherosclerosis; 2017 Nov; 266():234-239. PubMed ID: 28864204
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fluorescent advanced glycation end products and their soluble receptor: the birth of new plasmatic biomarkers for risk stratification of acute coronary syndrome.
    Raposeiras-Roubín S; Rodiño-Janeiro BK; Paradela-Dobarro B; Grigorian-Shamagian L; García-Acuña JM; Aguiar-Souto P; Jacquet-Hervet M; Reino-Maceiras MV; González-Juanatey JR; Álvarez E
    PLoS One; 2013; 8(9):e74302. PubMed ID: 24058542
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma levels of soluble receptor for advanced glycation end products are associated with endothelial function and predict cardiovascular events in nondiabetic patients.
    Chiang KH; Huang PH; Huang SS; Wu TC; Chen JW; Lin SJ
    Coron Artery Dis; 2009 Jun; 20(4):267-73. PubMed ID: 19440065
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modulation of high sensitivity C-reactive protein by soluble receptor for advanced glycation end products.
    McNair ED; Wells CR; Mabood Qureshi A; Basran R; Pearce C; Orvold J; Devilliers J; Prasad K
    Mol Cell Biochem; 2010 Aug; 341(1-2):135-8. PubMed ID: 20339904
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma S100A12 and soluble receptor of advanced glycation end product levels and mortality in chronic kidney disease Stage 5 patients.
    Isoyama N; Leurs P; Qureshi AR; Bruchfeld A; Anderstam B; Heimburger O; Bárány P; Stenvinkel P; Lindholm B
    Nephrol Dial Transplant; 2015 Jan; 30(1):84-91. PubMed ID: 25074436
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improved long-term clinical outcomes in patients with ST-elevation myocardial infarction undergoing remote ischaemic conditioning as an adjunct to primary percutaneous coronary intervention.
    Sloth AD; Schmidt MR; Munk K; Kharbanda RK; Redington AN; Schmidt M; Pedersen L; Sørensen HT; Bøtker HE;
    Eur Heart J; 2014 Jan; 35(3):168-75. PubMed ID: 24031025
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Soluble receptors for advanced glycation end products (sRAGE) as a predictor of restenosis following percutaneous coronary intervention.
    McNair ED; Wells CR; Mabood Qureshi A; Basran R; Pearce C; Orvold J; Devilliers J; Prasad K
    Clin Cardiol; 2010 Nov; 33(11):678-85. PubMed ID: 21089112
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Higher plasma soluble Receptor for Advanced Glycation End Products (sRAGE) levels are associated with incident cardiovascular disease and all-cause mortality in type 1 diabetes: a 12-year follow-up study.
    Nin JW; Jorsal A; Ferreira I; Schalkwijk CG; Prins MH; Parving HH; Tarnow L; Rossing P; Stehouwer CD
    Diabetes; 2010 Aug; 59(8):2027-32. PubMed ID: 20522598
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The soluble receptor for advanced glycation end-products (sRAGE) has a dual phase-dependent association with residual cardiovascular risk after an acute coronary event.
    Grauen Larsen H; Yndigegn T; Marinkovic G; Grufman H; Mares R; Nilsson J; Goncalves I; Schiopu A
    Atherosclerosis; 2019 Aug; 287():16-23. PubMed ID: 31181415
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dynamic fluctuations of advanced glycation end products and its C-terminal truncated receptor level in patients with acute ST-segment elevation myocardial infarction and undergoing diabetes or not: A retrospective study.
    Qiu H; Li WP; Shen XH; Guo XY; Hua B; Li HW
    Medicine (Baltimore); 2018 Jul; 97(30):e11278. PubMed ID: 30045252
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is there any evidence that AGE/sRAGE is a universal biomarker/risk marker for diseases?
    Prasad K
    Mol Cell Biochem; 2019 Jan; 451(1-2):139-144. PubMed ID: 29961210
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Soluble receptor for advanced glycation end products in critically ill patients and its associations with other clinical markers and 28-day mortality.
    Cheng Y; Zhong J; Xiang Y; Zeng F; Cai D; Zhao L
    Clin Interv Aging; 2014; 9():1981-6. PubMed ID: 25429209
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term physical activity leads to a significant increase in serum sRAGE levels: a sign of decreased AGE-mediated inflammation due to physical activity?
    Sponder M; Campean IA; Emich M; Fritzer-Szekeres M; Litschauer B; Graf S; Dalos D; Strametz-Juranek J
    Heart Vessels; 2018 Aug; 33(8):893-900. PubMed ID: 29368166
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of cardiovascular risk factors and medication use on the efficacy of remote ischaemic conditioning: post hoc subgroup analysis of a randomised controlled trial.
    Sloth AD; Schmidt MR; Munk K; Schmidt M; Pedersen L; Sørensen HT; Bøtker HE;
    BMJ Open; 2015 Apr; 5(4):e006923. PubMed ID: 25838505
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of preinfarction angina and coronary collateral blood flow on the efficacy of remote ischaemic conditioning in patients with ST segment elevation myocardial infarction: post hoc subgroup analysis of a randomised controlled trial.
    Pryds K; Bøttcher M; Sloth AD; Munk K; Rahbek Schmidt M; Bøtker HE;
    BMJ Open; 2016 Nov; 6(11):e013314. PubMed ID: 27884851
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum levels of sRAGE, the soluble form of receptor for advanced glycation end products, are associated with inflammatory markers in patients with type 2 diabetes.
    Nakamura K; Yamagishi S; Adachi H; Kurita-Nakamura Y; Matsui T; Yoshida T; Imaizumi T
    Mol Med; 2007; 13(3-4):185-9. PubMed ID: 17592553
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.